menu
    • menu

    Company profile for Polyphor

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical stage, Swiss biopharmaceutical company leading the research and development of a new mechanism of action in solid tumors, CXCR4 inhibition, for combination treatment in oncology. Balixafortide, an innovative molecule based on our inhouse macrocycle chemistry, is developed for treatment of metastatic breast cancer. Balixafortide is a potent and highly selective blocker of CXCR4, a G-protein coupled receptor (G...
    We are a clinical stage, Swiss biopharmaceutical company leading the research and development of a new mechanism of action in solid tumors, CXCR4 inhibition, for combination treatment in oncology. Balixafortide, an innovative molecule based on our inhouse macrocycle chemistry, is developed for treatment of metastatic breast cancer. Balixafortide is a potent and highly selective blocker of CXCR4, a G-protein coupled receptor (GPCR) that regulates the trafficking and homing of both cancer cells and cells of the patient’s immune system.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PolyphorSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hegenheimermattweg 125 CH-4123 Allschwil
    Telephone
    Telephone
    +41 61 567 16 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.polyphor.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Polyphor Closes Merger with EnBiotix and is Renamed Spexis
    Polyphor Closes Merger with EnBiotix and is Renamed Spexis

    31 Dec 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/polyphor-closes-merger-with-enbiotix-and-is-renamed-spexis/?s=79

    BIOSPACE
    31 Dec 2021
    Share Share
    Polyphor & EnBiotix Announce Signing of Merger Agreement and Sale
    Polyphor & EnBiotix Announce Signing of Merger Agreement and Sale

    01 Sep 2021

    // ACCESSWIRE

    https://www.accesswire.com/662404/Polyphor-and-EnBiotix-Announce-Signing-of-Merger-Agreement-and-Sale-of-Inhaled-Murepavadin-to-EnBiotix

    ACCESSWIRE
    01 Sep 2021
    Share Share
    Polyphor provides update on the future of the FORTRESS study of balixafortide
    Polyphor provides update on the future of the FORTRESS study of balixafortide

    19 Jul 2021

    // BLOOMBERG

    https://www.bloomberg.com/press-releases/2021-07-16/eqs-adhoc-polyphor-provides-update-on-the-future-of-the-fortress-study-of-balixafortide-and-announces-initial-restructuring

    BLOOMBERG
    19 Jul 2021
    Share Share
    Polyphor flops a phase 3, jeopardizing its future
    Polyphor flops a phase 3, jeopardizing its future

    28 Jun 2021

    // FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/polyphor-flops-a-phase-3-jeopardizing-its-future-as-shares-more-than-halved

    FIERCEBIOTECH
    28 Jun 2021
    Share Share
    Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide
    Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide

    28 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/28/2253544/0/en/Polyphor-Provides-Update-on-the-Phase-III-FORTRESS-Study-of-Balixafortide-in-Patients-With-Advanced-HER2-Negative-Breast-Cancer.html

    GLOBENEWSWIRE
    28 Jun 2021
    Share Share
    Polyphor's breast cancer candidate shows promise in COVID-19
    Polyphor's breast cancer candidate shows promise in COVID-19

    07 Jun 2021

    // FIERCEBIOTECH

    https://www.fiercebiotech.com/research/a-breast-cancer-candidate-for-covid-19-polyphor-s-drug-shows-dual-action-early-studies

    FIERCEBIOTECH
    07 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search